Clinical Factors Impacting Outcomes From Failed Trabeculectomy Leading to Glaucoma Drainage Device Implantation and Subsequent Penetrating Keratoplasty.
Journal
Journal of glaucoma
ISSN: 1536-481X
Titre abrégé: J Glaucoma
Pays: United States
ID NLM: 9300903
Informations de publication
Date de publication:
01 09 2023
01 09 2023
Historique:
received:
19
11
2022
accepted:
12
04
2023
pmc-release:
01
09
2024
medline:
31
8
2023
pubmed:
12
5
2023
entrez:
12
5
2023
Statut:
ppublish
Résumé
We evaluated the factors that impacted time from glaucoma drainage implant (GDI) surgery to penetrating keratoplasty (PK) in eyes with previously clear corneas (ie, GDI-first sequence), and that specifically underwent a trabeculectomy before GDI surgery for intraocular pressure (IOP) control. To describe through an event-triggered data collection method the clinical course and the long-term outcomes of 2 procedures that are commonly performed sequentially in complex clinical situations: GDI surgery and PK. The study investigates the clinical factors associated with the progression to PK and determines the GDI success rate and graft survival. A single, tertiary-care center retrospective interventional cases series including patients with a sequential history of trabeculectomy, GDI surgery, and PK from 1999 to 2009. Outcome measures included IOP, visual acuity, graft failure, GDI failure, and time from GDI to PK. Of the eyes, 56% had primary open angle glaucoma. The time from the last trabeculectomy to GDI was 66.5 ± 66.7 months. Of the eyes, 84% received a Baerveldt GDI. Time from GDI to PK was 36.4 ± 28.4 months. IOP at the time of PK was between 5 mm Hg and 21 mm Hg in 90% of eyes. At the last follow-up, 48% of grafts were clear. At 5 years post-PK, 33% of corneal grafts remained clear, whereas 81% of tubes remained functional. Nearly half of the corneal grafts are clear at the last long-term follow-up. Graft failure occurs at a higher rate than tube failure suggesting that IOP control is only one and possibly not the most important factor in graft survival in eyes with prior glaucoma surgery.
Identifiants
pubmed: 37171992
doi: 10.1097/IJG.0000000000002239
pii: 00061198-990000000-00216
pmc: PMC10524893
mid: NIHMS1899240
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
800-806Subventions
Organisme : NEI NIH HHS
ID : P30 EY014801
Pays : United States
Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
Disclosure: S.H.Y. is a consultant of Alcon, Allergan, Carl Zeiss Meditec, Bioptigen, Bausch and Lomb, and Transcend Medical. R.K.L. is supported by the Walter G. Ross Foundation. The remaining authors declare no conflict of interest.
Références
Ophthalmology. 2007 Dec;114(12):2281-6
pubmed: 18054642
Indian J Ophthalmol. 2008 Jul-Aug;56(4):269-77
pubmed: 18579984
Am J Ophthalmol. 2022 Jun;238:27-35
pubmed: 34995525
Cornea. 2007 Oct;26(9):1060-6
pubmed: 17893534
Ophthalmology. 1987 Jul;94(7):871-4
pubmed: 3309771
Graefes Arch Clin Exp Ophthalmol. 2005 Dec;243(12):1284-7
pubmed: 15940484
Ophthalmology. 1993 Nov;100(11):1728-35
pubmed: 8233403
Am J Ophthalmol. 2004 Aug;138(2):200-5
pubmed: 15289127
Cornea. 2007 Dec;26(10):1285-7
pubmed: 18043196
Am J Ophthalmol. 2010 Aug;150(2):169-78
pubmed: 20537311
Ophthalmology. 2001 Feb;108(2):279-84
pubmed: 11158799
Ann Ophthalmol. 1979 May;11(5):809-11
pubmed: 380442
Curr Opin Ophthalmol. 2016 Mar;27(2):132-9
pubmed: 26595847
Am J Ophthalmol. 1997 Jan;123(1):54-61
pubmed: 9186097
J Glaucoma. 2018 May;27(5):440-444
pubmed: 29521717
Saudi J Ophthalmol. 2020 Nov 22;34(1):1-7
pubmed: 33542979
Br J Ophthalmol. 2007 Jun;91(6):739-42
pubmed: 17301121
Invest Ophthalmol. 1975 Mar;14(3):173-6
pubmed: 123231
Ophthalmology. 2022 Aug;129(8):841-855
pubmed: 35331751
Can J Ophthalmol. 1993 Oct;28(6):254-8
pubmed: 8299048
J Glaucoma. 2012 Dec;21(9):608-14
pubmed: 21602705
Eye (Lond). 1988;2 ( Pt 5):583-90
pubmed: 3076870
J Glaucoma. 2019 Oct;28(10):906-910
pubmed: 31393312
Graefes Arch Clin Exp Ophthalmol. 2018 Oct;256(10):1953-1960
pubmed: 29926168
J Glaucoma. 2021 Feb 1;30(2):170-174
pubmed: 33955946
Aust N Z J Ophthalmol. 1993 May;21(2 Suppl):1-48
pubmed: 8333942
Am J Ophthalmol. 1985 Oct 15;100(4):593-5
pubmed: 3901771
Cornea. 2012 Apr;31(4):350-8
pubmed: 22222999
Ophthalmology. 2001 Nov;108(11):1978-85
pubmed: 11713065
Ophthalmic Surg Lasers Imaging. 2011 Sep-Oct;42(5):394-9
pubmed: 21899244
Ophthalmology. 2001 Feb;108(2):272-8
pubmed: 11158798
Int Ophthalmol. 2016 Aug;36(4):541-6
pubmed: 26646776
Ophthalmology. 2021 Jan;128(1):30-38
pubmed: 32598949
Ophthalmology. 2001 Jun;108(6):1050-8
pubmed: 11382628
Ophthalmol Glaucoma. 2021 Jan-Feb;4(1):32-41
pubmed: 32739403
Ophthalmic Surg. 1992 Oct;23(10):666-71
pubmed: 1306663
Ophthalmology. 2013 Nov;120(11):2232-40
pubmed: 23796764
Cornea. 2010 Mar;29(3):278-82
pubmed: 20118781
Am J Ophthalmol. 2013 Mar;155(3):530-5
pubmed: 23218690
Ophthalmology. 2012 Apr;119(4):694-702
pubmed: 22196977
Ophthalmology. 2007 Dec;114(12):2265-70
pubmed: 17466376
J Ophthalmol. 2012;2012:576394
pubmed: 22315661
Clin Exp Ophthalmol. 2003 Dec;31(6):492-5
pubmed: 14641156
Curr Opin Ophthalmol. 2009 Mar;20(2):122-5
pubmed: 19240544
Ophthalmology. 2015 Feb;122(2):308-16
pubmed: 25439606
Ophthalmol Glaucoma. 2021 Jan-Feb;4(1):20-31
pubmed: 32830103
Am J Ophthalmol. 2012 May;153(5):804-814.e1
pubmed: 22244522
Am J Ophthalmol. 2012 May;153(5):789-803.e2
pubmed: 22245458
Graefes Arch Clin Exp Ophthalmol. 1997 Sep;235(9):553-7
pubmed: 9342604
Graefes Arch Clin Exp Ophthalmol. 2018 Nov;256(11):2191-2200
pubmed: 30171351
Arch Ophthalmol. 2003 Aug;121(8):1087-92
pubmed: 12912684
Ophthalmology. 2021 Feb;128(2):218-226
pubmed: 32603727
Arch Ophthalmol. 2002 Jun;120(6):701-13; discussion 829-30
pubmed: 12049574
Cornea. 1995 Jan;14(1):26-32
pubmed: 7712732